Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19173048 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL29125008 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL2744005 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL30954764 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL203262 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL19172281 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL23015072 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1069647 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL2786532 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1008189 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332112-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4574172-A2 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2025-06-25 | — | — | EP | disclosed |
| EP-4466250-B1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4466250-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2024-11-27 | — | — | EP | disclosed |
| CN-118922401-A | Ionizable cationic lipids for lipid nanoparticles | 盖纳万科学有限公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2023144798-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023144798-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2023-08-03 | — | — | WO | disclosed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-11365183-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| US-5114940-A | Insecticides or anthelmintics from fused ring heterocycles containing amides or thioamides | ROUSSEL-UCLAF (FR) | 1992-05-19 | — | — | US | disclosed |
| EP-0317188-A2 | Heteroaromatic enamide derivatives and their use as pesticides | ROUSSEL UCLAF (FR) | 1989-05-24 | — | — | EP | disclosed |
| EP-0282940-A2 | A method for the preparation of a gamma-substituted (E)-2-alken-1-AL | Shin-Etsu Chemical Co., Ltd. (JP) | 1988-09-21 | — | — | EP | disclosed |
| EP-0228222-A2 | Pesticidal dihalovinylalkenylamides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-07-08 | — | — | EP | disclosed |
| EP-0022634-B1 | ACYLATED INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS AND DRUGS COMPRISING THEM | TEIJIN LIMITED (JP) | 1983-04-06 | — | — | EP | disclosed |
| US-4317905-A | Preparation of compounds containing two conjugated double bonds cis-cis and cis-trans | MONTEDISON S.P.A. (IT) | 1982-03-02 | — | — | US | disclosed |
| EP-0022634-A1 | Acylated indole derivatives, processes for their preparation and pharmaceutical compositions and drugs comprising them | TEIJIN LIMITED (JP) | 1981-01-21 | — | — | EP | disclosed |
| EP-0011169-A1 | Process for the stereo-selective preparation of (E),(E)-diolefines | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-05-28 | — | — | EP | disclosed |
| US-4089897-A | Geminal prostaglandin analogs | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1978-05-16 | — | — | US | disclosed |
| US-4090019-A | Geminal prostaglandin analogs | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | MEN1 1907/4885KMT2A 813/4885KDM4C 480/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | MEN1 1907/4885KMT2A 813/4885KDM4C 480/4885 |
| US-11365183-B2 | Eicosanoid derivatives | FABP3, PTGER3, PTGES3 | MEN1 4701/4885KMT2A 4627/4885KDM4C 4722/4885 |
| US-20250332112-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | CETP, NPC1L1, ABCB4 | MEN1 2023/4885KMT2A 2016/4885KDM4C 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.